TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1764941

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 30 micrograms/day (LN 30)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norethisterone 350 micrograms/day (NE 350)
Number of subjects: 0
Study: 6299620

Group type: EXPERIMENTAL
Intervention: 1 mg of the met-enkephalin analogue, DAMME
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16 mg of the opiate antagonist, naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycaemia (0.15 u/kg) or naloxone (25 mg)
Number of subjects: 0
Study: 29607741

Group type: EXPERIMENTAL
Intervention: Intragastric quinine-hydrochloride (QHCl, 10 µmol/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study: 28671901

Group type: EXPERIMENTAL
Intervention: Extended visitation model (12 hr/d)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Restricted visitation model (4.5 hr/d)
Number of subjects: 286
Study: 26550976

Group type: EXPERIMENTAL
Intervention: Glaucoma follow-up unit
Number of subjects: 815

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 815
Study: 25171216

Group type: EXPERIMENTAL
Intervention: Treadmill training and anodal stimulation of the primary motor cortex
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treadmill training and placebo transcranial direct‐current stimulation
Number of subjects: 24
Study: 22217196

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (BMI <30)
Number of subjects: 219
Study: 20667840

Group type: EXPERIMENTAL
Intervention: Looped NGT feeding
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional adhesive dressing
Number of subjects: 104
Study: 17405568

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resynchronization therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term circulatory assistance
Number of subjects: 0
Study: 15618785

Group type: EXPERIMENTAL
Intervention: Esmolol bolus of 1 mg/kg followed by a continuous infusion of 150 microg.kg.min
Number of subjects: 10

Group type: COMPARATOR
Intervention: No beta‐blockade (control)
Number of subjects: 10
Study: 12477060

Group type: EXPERIMENTAL
Intervention: Tazarotene gel 0.1% b.i.d. for eight consecutive weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9174183

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) at a dose of 2.8 to 3.0 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate at a standard dose of 1.0 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome)
Number of subjects: 10
Study: 8417638

Group type: EXPERIMENTAL
Intervention: Logistic regression or proportional hazards analysis
Number of subjects: 60
Study: 3096782

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MTC) administered orally in daily doses from 20 to 7.5 mg for 10 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28587472

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 27332626

Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 24819106

Group type: EXPERIMENTAL
Intervention: Translumbar and transsacral magnetic stimulation
Number of subjects: 70
Study: 22469706

Group type: EXPERIMENTAL
Intervention: Laparoscopic HIPEC in a neo-adjuvant setting (12 patients)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Laparoscopic HIPEC in an adjuvant setting (19 patients)
Number of subjects: 31
Study: 20707784

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Selegiline with high 'drive' scores on the BAS
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo with high 'drive' scores on the BAS
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Selegiline with low 'drive' scores on the BAS
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo with low 'drive' scores on the BAS
Number of subjects: 243
Study: 18517143

Group type: EXPERIMENTAL
Intervention: Strength training-enhanced program (TR+ST), n = 10
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional pulmonary rehabilitation program (TR), n = 10
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Strength training-enhanced program (TR+ST)
Number of subjects: 20
Study: 15851647

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24897

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 24897

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 24897
Study: 12455427

Group type: EXPERIMENTAL
Intervention: 6-session cognitive-behavioral therapy (CBT) in conjunction with usual TMD treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual conservative treatment by TMD specialist dentists
Number of subjects: 0
Study: 10501817

Group type: EXPERIMENTAL
Intervention: Iloprost infusion (3 ng kg(‐1) min(‐1) for 5 h) for 1 day (short-term treatment)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Iloprost infusion (3 ng kg(‐1) min(‐1) for 5 h) over a period of 28 days (long-term treatment)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline infusion (for 5 h) for 1 day (control treatment)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline infusion over a period of 28 days (placebo treatment)
Number of subjects: 13
Study: 8931888

Group type: EXPERIMENTAL
Intervention: New sustained release formulation of diltiazem (120 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation of diltiazem (120 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study: 1320559

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 0
Study: 6435999

Group type: EXPERIMENTAL
Intervention: Lopirazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30333359

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid 250 mg twice a day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Tranexamic acid microinjections (4 mg/ml) monthly
Number of subjects: 64
Study: 29500065

Group type: EXPERIMENTAL
Intervention: Docetaxel (75mg/m2) as first-line chemotherapy
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 or 25mg/m2) as first-line chemotherapy
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 or 25mg/m2) as second-line chemotherapy
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Patients with PSA response
Number of subjects: 571
Study: 26860838

Group type: EXPERIMENTAL
Intervention: 3DATG (group 1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CT (group 2)
Number of subjects: 36
Study: 25249651

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 22374059

Group type: EXPERIMENTAL
Intervention: Local pressure with gauze soaked with tranexamic acid
Number of subjects: 23

Group type: COMPARATOR
Intervention: Local pressure with gauze without tranexamic acid
Number of subjects: 23
Study: 21344797

Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis L. (3 x 2 p.c. for 4 days and then 2 x 2 p.c. for 3 days)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Micronised purified flavanoid fraction (MPFF) (3 x 2 p.c. for 4 days and then 2 x 2 p.c. for 3 days)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo (3 x 2 p.c. for 4 days and then 2 x 2 p.c. for 3 days)
Number of subjects: 570
Study: 16791905

Group type: COMPARATOR
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study: 16236850

Group type: EXPERIMENTAL
Intervention: Nurse-assisted medical management (MM)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Nurse-assisted collaborative management (CM)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 151
Study: 12147790

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor antagonists (ARB)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Blood pressure control strategies
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (AHM) increase
Number of subjects: 304

Group type: COMPARATOR
Intervention: No AHM increase
Number of subjects: 304

Group type: COMPARATOR
Intervention: ACEI or ARB non-use
Number of subjects: 304
Study: 9504938

Group type: EXPERIMENTAL
Intervention: Bosentan 500 mg once daily
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Bosentan 1000 mg twice daily
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study: 7635228

Group type: EXPERIMENTAL
Intervention: Single ultrasound estimation of fetal weight at 37 weeks of gestation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Repeated ultrasound estimations of fetal weight (at 28, 31, 34, and 37 weeks)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Linear extrapolation from two estimates
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Extrapolation by a second order polynomial fitted to four estimates
Number of subjects: 1000
Study: 2468148

Group type: EXPERIMENTAL
Intervention: TX mode (rate responsive pacing)
Number of subjects: 18

Group type: COMPARATOR
Intervention: VVI mode (fixed rate ventricular inhibited pacing)
Number of subjects: 18
Study: 1152314

Group type: EXPERIMENTAL
Intervention: Puppet therapy (puppet show designed to familiarize patients with hospital routines and procedures)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nontreatment group (control)
Number of subjects: 43
Study: 28371025

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, taken 1 hour before sexual activity, adjustable to 100 or 25 mg)
Number of subjects: 9413
Study: 26521575

Group type: EXPERIMENTAL
Intervention: Scalp electric acupuncture (EA) under anatomic orientation combined with rehabilitation training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple rehabilitation training
Number of subjects: 60
Study: 22901492

Group type: EXPERIMENTAL
Intervention: Midwife-led unit (MU)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Standard obstetric unit (SCU)
Number of subjects: 1110
Study: 20479480

Group type: EXPERIMENTAL
Intervention: Hypnosis (n = 30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Video attention-control (n = 29)
Number of subjects: 59
Study: 19047704

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 173

Group type: COMPARATOR
Intervention: Bracing
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Hypothetical trial participation
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Decision-making responsibility
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Treatment satisfaction
Number of subjects: 173
Study: 16463842

Group type: EXPERIMENTAL
Intervention: Xenon‐enhanced computerized tomography (Xe‐CT)
Number of subjects: 43
Study: 12576441

Group type: EXPERIMENTAL
Intervention: CD40 positive group
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CD23 positive group
Number of subjects: 125
Study: 10326966

Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation syndrome
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Age-related macular degeneration
Number of subjects: 777
Study: 7491349

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no LTOT)
Number of subjects: 85
Study: 1685841

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (Actiderm) plus triamcinolone acetonide (TAA) 0.1% cream applied every third day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% cream applied twice daily for 4 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Actiderm plus TAA
Number of subjects: 19
Study: 7199333

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ataralgesic combinations
Number of subjects: 0
Study: 28758261

Group type: EXPERIMENTAL
Intervention: Picosecond lasers
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nanosecond laser
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Picosecond lasers (monochromic black or blue tattoos)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nanosecond laser (monochromic black or blue tattoos)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Picosecond lasers (polychromic tattoos)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nanosecond laser (polychromic tattoos)
Number of subjects: 49
Study: 27140187

Group type: EXPERIMENTAL
Intervention: No area under the noseband (NAUN)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Half conventional area under noseband (HCAUN)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unfastened noseband (UN)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional area under noseband (CAUN)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-removal of noseband and double bridle
Number of subjects: 12
Study: 24731567

Group type: EXPERIMENTAL
Intervention: Intensive-dose atorvastatin therapy (IAT, 40mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard-dose atorvastatin therapy (SAT, 20mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-dose atorvastatin therapy (LAT, 10mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All treatment groups (IAT, SAT, LAT)
Number of subjects: 120
Study: 22466997

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P1, n = 33)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P1)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Non-pulsatile perfusion (Group NP)
Number of subjects: 85
Study: 19936872

Group type: EXPERIMENTAL
Intervention: SRP, chlorhexidine gel 0.5%, three sessions of KTP laser irradiation
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: SRP, three sessions of KTP laser irradiation
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: SRP, irrigation with povidone-iodine 10%, three sessions of KTP laser irradiation
Number of subjects: 730

Group type: COMPARATOR
Intervention: SRP, chlorhexidine gel 0.5%
Number of subjects: 730
Study: 18024088

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15964561

Group type: EXPERIMENTAL
Intervention: Advance testing for CRP and WBC
Number of subjects: 305

Group type: COMPARATOR
Intervention: No advance testing
Number of subjects: 305
Study: 12601104

Group type: EXPERIMENTAL
Intervention: 20 mg sumatriptan nasal spray
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 10229408

Group type: EXPERIMENTAL
Intervention: Controlled release oxycodone
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Immediate release oxycodone-APAP
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 8740103

Group type: EXPERIMENTAL
Intervention: Foscarnet 90 mg/kg b.i.d. 5 days for 3 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Foscarnet 90 mg/kg b.i.d. daily (7 days a week)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 36
Study: 1928165

Group type: EXPERIMENTAL
Intervention: Heparin-bonded PA catheters made of polyvinylchloride or polyurethane
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Heparin-bonded PA catheters
Number of subjects: 297
Study: 6351455

Group type: EXPERIMENTAL
Intervention: Norfenefrin infusion (2-4 mg/kg per minute)
Number of subjects: 12
Study: 31596615

Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (PE) for 20 minutes in underwater conditions (WET)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High physical exercise (PE) for 20 minutes in underwater conditions (WET)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Inactivity (DRY) in laboratory conditions
Number of subjects: 27
Study: 31522562

Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine in women
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine in men
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine in women with CAD
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine in women without CAD
Number of subjects: 336
Study: 30199861

Group type: EXPERIMENTAL
Intervention: Tretinoin Loaded Nanoemulsion (NE-TRE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% Tretinoin Emulsion (Control)
Number of subjects: 0
Study: 26861783

Group type: EXPERIMENTAL
Intervention: Empagliflozin administration
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Chronic (4 weeks) empagliflozin administration
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Empagliflozin in patients with T2D
Number of subjects: 91
Study: 24717964

Group type: EXPERIMENTAL
Intervention: JE-CV
Number of subjects: 300

Group type: COMPARATOR
Intervention: SA14-14-2
Number of subjects: 300
Study: 22458741

Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine (T/A) single-pill combination (SPC)
Number of subjects: 858
Study: 21126301

Group type: EXPERIMENTAL
Intervention: Regular clinic services plus nine follow-up phone calls over 12 months
Number of subjects: 805

Group type: COMPARATOR
Intervention: Regular clinic services
Number of subjects: 805
Study: 17011678

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) injection of 0.1 ml dose of inactivated split‐virion influenza vaccine
Number of subjects: 500

Group type: COMPARATOR
Intervention: Intramuscular (IM) injection of 0.5 ml dose of inactivated split‐virion influenza vaccine
Number of subjects: 500
Study: 15843666

Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg weekly for one year
Number of subjects: 4012

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4012
Study: 12415035

Group type: EXPERIMENTAL
Intervention: Coaching for ETS exposure reduction (7 coaching sessions, approximately 45 minutes each)
Number of subjects: 204

Group type: COMPARATOR
Intervention: No additional service (control condition)
Number of subjects: 204
Study: 10387506

Group type: EXPERIMENTAL
Intervention: Health promotion program focusing on nutrition and physical activity over 16 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Health promotion program
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Focus groups feedback
Number of subjects: 34
Study: 7569455

Group type: EXPERIMENTAL
Intervention: 30 µg of estrogen and 300 µg of progestogen (Group 2)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 35 µg of estrogen and 500 µg of progestogen (Group 3)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 30 µg of levonorgestrel (Group 4)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Intrauterine devices (Group 1)
Number of subjects: 371
Study: 2169779

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg (additional doses for breakthrough nausea)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Granisetron (40-240 micrograms/kg)
Number of subjects: 296
Study: 6986949

Group type: EXPERIMENTAL
Intervention: Captopril, 100 mg orally
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31647036

Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-fat meals
Number of subjects: 8
Study: 27735931

Group type: EXPERIMENTAL
Intervention: Inhaled hydrofluoalkane-beclomethasone dipropionate (QVAR) 100 μg per dose, twice daily via Aerochamber with face mask
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 25230894

Group type: EXPERIMENTAL
Intervention: Circuit exercise training (1 hour, three times a week for 12 weeks)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Circuit exercise training
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 98
Study: 23949258

Group type: EXPERIMENTAL
Intervention: EHK02‐01 cream applied twice daily for 28 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control cream applied twice daily for 28 days
Number of subjects: 65
Study: 22575040

Group type: EXPERIMENTAL
Intervention: L-alanylglutamine (AlaGln) at 89 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-glutamine (L-Gln) at 60 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enzymatically hydrolyzed wheat protein (HWP) at 200 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 8
Study: 19412108

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.03‐0.1 microg kg min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl (1‐3 microg kg) and midazolam (0.05‐0.1 mg kg)
Number of subjects: 50
Study: 17380360

Group type: EXPERIMENTAL
Intervention: Power water‐assisted liposuction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional liposuction
Number of subjects: 60
Study: 15356368

Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide antimicrobial gauze
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control gauze without polyhexamethylene biguanide
Number of subjects: 21